* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周三早盘涨幅扩大至8%，创2023年2月2日以来新高。
* 该公司此前公告称，贝莫苏拜单抗注射液联合盐酸安罗替尼胶囊对比帕博利珠单抗注射液一线治疗PD-L1阳性晚期非小细胞肺癌的III期临床试验达到无进展生存期$(PFS)$的主要研究终点，在TPS（肿瘤细胞阳性比例分数）≥50%的人群中，中位PFS较帕博利珠单抗组延长超过6个月，疾病进展╱死亡风险降低40%。
帕博利珠单抗是默沙东研发生产的抗肿瘤药物，是目前最畅销的癌症免疫治疗药物之一。
* 中国生物制药今年迄今涨47.2%，同期恒生指数.HSI上扬17.8%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度升4.9%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 吴云凌)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.